New Delhi, Oct. 1 -- The Central Drugs Standard Control Organisation (CDSCO), India's drug controller, has approved Ozempic (semaglutide) for use in adults with type 2 diabetes. The Ozempic launch in India is a significant development amid an ongoing rise in diabetic patients in India.

Novo Nordisk, the Danish pharmaceutical giant, is set to launch Ozempic in India soon.

According to sources quoted by PTI, Ozempic, the once-a-week injection, will be available only on a doctor's prescription.

"Semaglutide Injection (Ozempic@) is indicated for the treatment of adults with Insufficiently Controlled Type 2 Diabetes Mellitus as an adjunct to Diet and Exercise," the approval by CDSCO said on September 26.

Ozempic received its initial approv...